OncoMatch/Liver Cancer (HCC)/CTNNB1 (β-catenin)
Liver Cancer (HCC)CTNNB1 (β-catenin) Clinical Trials
CTNNB1 activating mutations occur in approximately 25–35% of HCC and activate Wnt/β-catenin signaling. Importantly, CTNNB1-mutant HCC is associated with resistance to PD-1/PD-L1 checkpoint inhibitors due to immune exclusion, making biomarker-directed therapy particularly important. Trials investigate β-catenin pathway inhibitors, porcupine inhibitors targeting Wnt secretion, and combination strategies for this immunotherapy-resistant subgroup.
Top recruiting CTNNB1 (β-catenin) Liver Cancer (HCC) trials
Ranked by phase and US site count. See all 3 trials matched to your profile →
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
National Cancer Institute (NCI)
Browse other molecular targets with active Liver Cancer (HCC) trials.